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Abstract  
 
Background 
Polypharmacy is common among older persons who are also vulnerable to side effects. We 
aimed to characterize patients who on admission to a geriatric psychiatric hospital had major 
medication side effects interfering with daily performance.  
 
Methods 
Cross-sectional cohort study of patients consecutively admitted to a geriatric psychiatric 
hospital from 12/06/2006 to 10/24/2008. The UKU side effect rating scale was performed, 
and patients were divided into those with no/minor side effects versus those with major side 
effects. Blood levels of 56 psychotropic drugs and 27 safety laboratory tests were measured 
upon admission. 
 
Results 
Of 206 patients included in the analysis, 70 (34%) had major side effects related to drug 
treatment. The most frequent side effects were asthenia (31%), reduced salivation (31%), 
concentration difficulties (28%), memory impairment (24%) and orthostatic dizziness (18%). 
The significant characteristics predicting major side effects were female gender (OR=2.4, 
95% confidence interval (CI)=1.1-5.5), main diagnosis of affective disorder (OR=4.3, 
95%CI=1.5-12.3), unreported use of psychotropic medications (OR=2.0, 95%CI=1.0-4.1), a 
higher number of reported psychotropic medications (OR=1.7, 95%CI-1.2-2.3), a higher 
number of reported medications for somatic disorders (OR=1.2, 95%CI=1.1-1.5) and a higher 
score on the Charlson comorbidity index (OR=1.2, 95%CI=1.0-1.4) (r2=0.238, p<0.001). 
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Conclusions 
Clinicians should be especially aware of side effects related to drug treatment in geriatric 
psychiatric female patients with a high use of psychotropic and other medications and somatic 
comorbidity. Unreported use of psychotropic medications was also related to the risk for side 
effects, and clinicians should make an effort to ascertain all medications taken by geriatric 
psychiatric patients. 
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Introduction 
 
All psychotropic medications may cause unwanted effects (Lingjaerde et al., 1987). Among 
older persons, polypharmacy is common (Shah and Hajjar, 2012). With ageing, both the 
pharmacokinetics and the pharmacodynamics of medications change (Mangoni and Jackson, 
2004), resulting in an increased risk of medication’ side effects (Turnheim, 2004). Moreover, 
both a strong relationship between polypharmacy and psychiatric conditions (Tveito et al., 
2014), and between polypharmacy and negative clinical outcomes (Jyrkka et al., 2009; Maher 
et al., 2014) has been observed. When medications are developed, older persons are 
underrepresented (Konrat et al., 2012) or, even, excluded from clinical research (McMurdo et 
al., 2005), leading to less knowledge of the effects of medications in older people. Moreover, 
older patients are particularly prone to side effects of commonly used psychotropic 
medications (Madhusoodanan and Bogunovic, 2004; Masand, 2000; Mottram et al., 2006), 
and they are particularly susceptible to central nervous system effects (Trifiro and Spina, 
2011). 
 
Medication side effects are difficult to assess, especially in older people, as signs of ageing 
and functional decline due to other co-morbid disorders may overlap with medication side 
effects.  To the best of our knowledge the side effects of psychotropic medications in elderly 
psychiatric patients have not been comprehensively studied, except for studies of single 
medications or medication classes (Kurzthaler et al., 2001; Masand, 2000; Mottram et al., 
2006), comparative studies (Allard et al., 2004), and a recent study of side effects related to 
potentially inappropriate medications (Hefner et al., 2015). Studies on side effects in the 
elderly are needed because older psychiatric patients are at an increased risk of side effects 
due to polypharmacy and ageing. More knowledge about the side effects of psychotropic 
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medications, which are being utilized widely and also increasingly in the elderly (Lovheim et 
al., 2008; Olfson et al., 2014), is of importance. Moreover, characterization of subgroups at 
highest risk for psychotropic side effects among older patients is of value when managing 
older psychiatric patients. 
 
The UKU side effect rating scale was developed for use in psychotropic medication trials and 
clinical practice. It is a comprehensive rating scale with well-defined items, and it also 
contains a global assessment on how side effects of psychotropic medications may interfere 
with the patient’s daily peformance (Lingjaerde et al., 1987). 
 
The aim of this study was to use the UKU side effect scale to characterize patients who on 
admission to a geriatric psychiatric hospital had side effects that moderately or severely 
interfered with their daily performance.  
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Methods 
 
Participants 
This cross-sectional cohort study included all patients consecutively admitted to the 
Department of Geriatric Psychiatry at Diakonhjemmet Hospital in Oslo, Norway, during the 
study period between 12/06/2006 and 10/24/2008. The department admits patients aged ≥60 
years from a catchment area of approximately 250,000 inhabitants, requiring hospital 
admission due to psychiatric illnesses. Patients are admitted to one of three wards, treating 
affective disorders, psychotic disorders, and psychiatric and behavioural symptoms of 
dementia, respectively. In Norway, psychiatric services are publically funded. 
 
All patients admitted during the time period were invited to participate in the study. Exclusion 
criteria were as follows: patients admitted for planned electroconvulsive treatment; patients 
with a short expected stay (<7 days); and inability of patients and the next of kin to provide 
written informed consent.  
 
Of 372 patients who were eligible for inclusion, 57 declined participation, 28 were unable to 
give informed consent and had no relative that could give consent on their behalf, and 40 
patients withdrew their consent or were admitted to another department in the hospital during 
the study. The UKU side effect rating scale was missing in 30 patients, and for 11 patients 
other data were lacking, leaving a total of 206 patients (55%) with analyzable data in this 
study. 
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Assessments 
The UKU side effect rating scale was developed by The Committee on Clinical 
Investigations, a standing committee under the Scandinavian Society of Psychopharmacology, 
for use in medication trials and clinical practice (Lingjaerde et al., 1987). The scale consists 
of 61 defined items describing psychic, neurological, autonomic, cardiovascular and other 
side effects, and a global score. The scoring in this study was based on all relevant available 
information, both based on patient report, physicians’ observations and reports from the ward 
personnel. The UKU subscores cannot be used for deriving a meaningful total side effect 
score, but a total side effect evaluation is of interest. Therefore, a four-point Likert-scale 
global score was added to evaluate the influence that the patient´ side effect could have on the 
patient’s daily performance. For the present study, the patients were divided into two groups 
according to the global score: 1. Patients with no or minor side effects, defined as “none” or 
“mild”, 2. Patients with major side effects, defined as “moderate” or “severe” (effect on daily 
performance). The UKU side effect rating scale was performed on admission to the hospital 
by the treating physician. 
 
The Mini Mental Status Evaluation (MMSE) (Folstein et al., 1975) was carried out on 
admission. The scale consists of 20 items, has a minimum score of 0 and a maximum score of 
30. A higher score denotes better cognition. We also used the Charlson Comorbidity Index, a 
weighted index that measures somatic comorbidity and that takes into account the number and 
the seriousness of comorbid diseases (Charlson et al., 1987). The Charlson Index was scored 
based on all available medical information, and a higher score indicates more comorbidity. 
 
The psychiatric diagnoses of the patients were recorded upon discharge. They were given by 
the physician responsible for the patient during the hospital stay and were based on all 
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available information obtained during the patient’s stay. Four main diagnostic categories were 
created for this study: dementia; affective disorders; psychosis; and other psychiatric 
diagnoses. The category “other diagnoses” included mainly personality disorders, alcohol or 
drug dependency, and organic causes of psychiatric symptoms (including patients with 
delirium). 
 
Medication Use and Serum Analysis  
The referring physician´s information of the patient’s medication use was registered on 
admission. Serum samples were collected in the morning on the day after admission, before 
any morning medication was given to detect levels of 56 psychotropic medications, including 
all antidepressants and antipsychotics with market authorization in Norway, as well as the 
most commonly prescribed anticonvulsants and benzodiazepines, in all patients (Tveito et al., 
2014). The serum samples were analyzed at the Center for Psychopharmacology, 
Diakonhjemmet Hospital, Oslo, Norway. An ultra-performance liquid chromatography-mass 
spectrometry (UPLC-MS/MS) method, developed for routine therapeutic drug monitoring 
(TDM) at the Center for Psychopharmacology, was applied for the analyses of all 
medications, except for lithium. Lithium was analyzed using an ion-selective electrode 
measurement. Validation parameters for imprecision and inaccuracy were <15% for all 
analyses. All of the analytical assays were validated and certified for routine TDM. The 
laboratory has been accredited since 2007, NS-EN ISO 15189 Medical laboratories, particular 
requirements for quality and competence. A supra-therapeutic concentration of a medication 
was defined as “above the reference range”, as defined for each specific medication by the 
Center for Psychopharmacology. Unreported use was defined as use of one or more 
psychotropic medications detected in serum that was not reported by the referring physician.  
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Routine blood screen 
Routine blood tests were performed in all patients on admission to hospital. The blood screen 
included a total of 27 standard items (see appendix), of which 26 were analyzed at the 
hospital’s biochemical department. The tests included measurements of different 
haematological parameters, renal and liver function, markers of infection, concentration of 
vitamin B-12 and folic acid, electrolytes and glucose. Prolactin was analyzed at the 
endocrinological laboratory of Aker University Hospital, Oslo. 
 
Ethics 
The study was approved by the Regional Committee for Research Ethics in Norway and the 
Norwegian Medicines Agency. All patients or their next of kin (if the patients did not have 
the capacity to consent on their own) signed the informed consent form before participating in 
the study. 
 
Statistical Analysis 
IBM SPSS® Software version 22.0 (SPSS Inc., Chicago, IL, USA) was used for all statistical 
analyses. Mean values and standard deviation (SD) were calculated for continuous variables, 
and frequency distributions were reported for categorical variables. For comparison between 
groups, independent Student´s T-test was used for continuous variables and Chi Square was 
used for categorical variables.  
For the comparison of characteristics between the patients experiencing major side effects 
(moderately to severely impairment of daily performance) or minor side effects (mild or no 
impairment of daily functioning), a direct multiple logistic regression analysis was performed. 
Whether or not the patients had major side effects was entered as the dependent variable. 
Included in the regression analysis were 203 patients, three patients were missing due to lack 
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of serum analysis and information on unreported use of psychotropic medication. First, 
analyses were made without any correction (presented as unadjusted values). Then, adjusted 
analyses were performed.  Covariates, other than age and gender, were included if the 
variables differed between the two groups with a p-value <0.1 in bivariate analysis. Only the 
total number, not the subgroups of psychotropic medications were included, as it would have 
been impossible disentangle the individual contribution of specific medication groups. Age, 
gender, main diagnosis of affective disorder, main diagnosis of dementia, total number of 
psychotropic drugs, total number of somatic drugs, sum of the Charlson comorbidity index 
and unreported use of psychotropic drugs were entered as covariates. Main diagnosis of 
psychosis was not included, as no patient in this diagnostic group had major side effects.  
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Results 
 
Of the 206 patients included in the analysis (mean age: 77.6±8.9 years, female sex=71.4 %), 
70 (34%) had major side effects as per the UKU assessment, and 69 (99%) of these used 
psychotropic medications. A total of 136 patients (66%) had none or mild side effects as per 
the UKU assessment (hereafter referred to as no/minor side effects).  
Patient characteristics for the total group are shown in Table 1. The patients with major side 
effects differed significantly in bivariate analyses regarding several characteristics from the 
patients with no/minor side effects. Patients with major side effects were more often women 
(p=0.022), more likely to have a main diagnosis of affective disorder (p<0.001), used a higher 
number of medications for physical disorders (p<0.001), used a higher number of 
psychotropic medications (p<0.001), had more unreported use of psychotropic medications 
(p=0.044) and had more physical comorbidity measured by the Charlson comorbidity index 
(p=0.015). For the psychotropic medications and unreported use, information on the three 
largest groups of medications is included in the table, with both use of and unreported use of 
benzodiazepines being most frequent. 
 
Table 2 shows the frequency of side effects, grouped into five main categories: psychic, 
neurological, autonomic, cardiovascular and other side effects. The most frequent side effects 
for the total group were psychic and autonomic side effects, with 107 and 104 patients 
experiencing these, respectively. The mean number of side effects was highest for the psychic 
side effects (1.5 ±1.9). The five most common side effects considered as possible or probable 
were: asthenia (31%), reduced salivation (31%), concentration difficulties (28%), memory 
impairment (24%) and orthostatic dizziness (18%). 
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Table 3 shows the results from the multiple logistic regression analysis assessing the 
association between different patient characteristics and major versus no/minor side effects. 
After multivariable correction, characteristics that were significantly and independently 
associated with major side effects included female gender (OR=2.4, 95% CI=1.1-5.5), main 
diagnosis of affective disorder (OR=4.3, 95%CI=1.5-12.3), unreported use of psychotropic 
medications (OR=2.0, 95%CI=1.0-4.1), a higher number of reported psychotropic 
medications (OR=1.7, 95%=1.2-2.3), a higher number of reported medications for physical 
illnesses (OR=1.2, 95%CI=1.1-1.5) and higher score on the Charlson comorbidity index 
(OR=.2, 95%CI=1.0-1.4). The total variance explained by this model was 23.8 % (p<0.001). 
 
There were no differences between patients with no/minor compared to major side effects for 
any of the performed 27 blood tests, except for thyroxin concentration (16.2±3.0 for the 
no/minor side effect group vs. 17.1±3.0 in the major side effect group). The detailed results 
are shown in table 4. 
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Discussion 
 
Our study of 206 older psychiatric patients with an average age of 78 years admitted to a 
geriatric psychiatric hospital showed that female gender, main diagnosis of affective disorder, 
physical comorbidity, a higher number of both psychotropic and somatic medications and 
unreported psychotropic medications use were each independently associated with having 
major side effects that interfered moderately or severely with the patients’ performance.  
 
As for the specific psychiatric disorders, only a main diagnosis of affective disorder was 
significantly associated with experiencing severe medication side effects. Physical symptoms 
of depression or increased burden of physical complaints due to depression can be a 
diagnostic challenge in older patients with medical comorbidities (Drayer et al., 2005). We 
have previously shown that patients with affective disorders also used more psychotropic 
medications compared to the rest of the patients (Tveito et al., 2014), which can increase the 
risk of side effects, although having an affective disorder and the number of psychotropic 
medications were each independently associated with more major side effects in the adjusted 
analysis. 
 
In medicine in general, and in psychiatry in particular, it can be difficult to distinguish 
between side effects of psychotropic medications and the clinical symptoms of the disorder 
for which the medication is given (Lingjaerde et al., 1987; Mihanovic et al., 2009). Since 
older patients have more physical comorbidities and use more medications in general, the 
complexity of an already difficult assessment is further enhanced. The Charlson comorbidity 
index has been shown to be useful as a prognostic factor for (re)hospitalization and survival in 
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several somatic illnesses (Kobayashi et al., 2011). In older persons with mental disorders, 
physical comorbidity is particularly important to consider when assessing side effects of 
medications. Our study showed that patients with more comorbidities suffered more from 
major side effects. Notably, it was not possible to identify these patients by the routine 
biochemical blood screen on admission. There were no differences between patients with 
no/minor side effects and major side effects in any of the analyses, except for thyroxin, for 
which there was a minimal statistical difference with mean differences that are not considered 
clinically relevant. Moreover, the difference in thyroxin concentrations would not be 
significant after a correction for multiple testing (e.g. Bonferroni correction). Such a 
correction would be appropriate when analyzing 27 blood test results. 
 
The present study supports previous publications showing more severe side effects in women 
than in men (Barbui et al., 2005; Rademaker, 2001). Women differ from men both in 
incidence and presentation of side effects associated with psychotropic drugs, with a higher 
risk of weight gain and endocrinological side effects (Haack et al., 2009). This difference may 
partly be due to higher serum concentrations in women when corrected for dose (Waade et 
al., 2012), but a female vulnerability to neurological side effects has also been described 
(Bonelli et al., 2005). In a study of tolerability of antipsychotic medications, sex was the 
strongest determinant of the overall subjective tolerance, with women reporting reduced 
tolerability (Barbui et al., 2005). 
 
To our surprise, we did not find increasing age to be associated with having more major side 
effects, at least not within an elderly population. The relationship between age and increased 
sensitivity to medications has a clinical and theoretical basis (Uchida et al., 2009). Clinical 
guidelines recommend lower dosing for the older persons (Alexopoulos et al., 2004), but few 
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trials have directly compared older patients with younger patients (Uchida et al., 2009). A 
study of serum levels of antidepressants showed that although dose correction of serum 
concentrations were made, the levels in the older patients comparable to younger patients 
were higher (Waade et al., 2012). The explanation for the failing association between age and 
side effects could be that the present study was not designed to investigate the effects of age, 
and all the included patients were 60 years or older, restricting the age range within which 
differences would be observed.  
 
Our finding of an association between major side effects and a high number of psychotropic 
and somatic medications is consistent with previous studies that found a direct relationship 
between polypharmacy and medication complications in the ambulatory setting (Gandhi et 
al., 2000; Gurwitz et al., 2003). The present study indicates that polypharmacy is a risk factor 
for more severe side effects in geriatric psychiatric patients. This finding should be a reminder 
for clinicians that polypharmacy should be minimized as much as possible. However, 
reducing polypharmacy is not a trivial matter, as physical comorbidity that is common, as 
measured by the Charlson index in our study, and that often requires additional medication 
use was also independently associated with a higher risk of major effects. Thus, a reduction of 
the treatment of physical disorders might increase the severity of these conditions, which may 
in turn increase the vulnerability to side effects. 
 
Unreported use of psychotropic medications was also a risk factor for more severe side 
effects. To the best of our knowledge, our study is the first to assess and report this 
association. It is possible that patients with unreported use of psychotropic medications do not 
use these medications according to recommendations, which may make it more probable that 
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major side effects occur. Alternatively, patients who were older and more brittle or 
cognitively impaired may have forgotten to report to their referring doctor all the medications 
that they took.  
 
The results of this study need to be interpreted within its limitations. This was a cross-
sectional study of a heterogeneous sample of older patients admitted to a psychiatric hospital. 
In the analyses, we used the number of reported psychotropic medications, being aware that 
the drug analysis revealed substantial use of unreported medications (Tveito et al., 2014). 
Physical conditions as well as medications for physical disorders are possible contributors to 
the assessed side effects, and as the concentration of these medications were not measured in 
serum, we chose to study the number of reported medications, correcting for use of 
unreported psychotropic medications in the analysis. Further, different physicians performed 
the UKU side effect rating scale. Although all were experienced clinicians, and were trained 
to use the rating scale, this may have introduced inter-rater variability. This was not formally 
tested. There is also a risk of bias in the assessment in the direction of expected associations 
between psychotropic medications and side effects. Additionally, the use of multiple 
medications makes it difficult to distinguish the side effect contribution of each medication. 
The best way to study side effects would be to administer the UKU side effect scale before 
starting a new medication, but in an elderly population, nearly all patients already use 
multiple psychotropic medications upon admission to our geriatric psychiatric hospital. 
Finally, patients admitted to a hospital are a selected population, likely biasing the sample to a 
more severely ill population. On the other hand, only consenting patients or those with a next 
of kin were included.  
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Despite these limitations, strengths of this study include the fact that a consecutive sample 
was assessed, that a formal rating scale, the UKU, was administered to all patients before the 
global score was assigned, and that comprehensive safety laboratory tests, as well as uniquely, 
psychotropic drug levels were measured.  Moreover, since the UKU rating scale evaluates 
how side effects interfere with the patients´ daily performance, this assessment is perhaps a 
more clinically relevant assessment compared to those only considering symptoms, especially 
in the elderly, where performance of daily living skills is of particular importance. 
 
In conclusion, we were able to identify a number of patient, illness and treatment factors that 
were independently associated with major side effects in geriatric psychiatric patients. Based 
on these results, clinicians should be especially aware of side effects in geriatric psychiatric 
female patients with a high use of psychotropic and somatic medications and physical 
comorbidity. Since unreported use of psychotropic medications was also significantly related 
to the risk for more severe side effects, clinicians should ascertain all medications taken by 
geriatric psychiatric patients in order to avoid drug-drug interactions and devise the most 
appropriate treatment plan.  
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 T
able 1. C
haracteristics of 206 patients adm
itted to the D
epartm
ent of G
eriatric Psychiatry, D
iakonhjem
m
et H
ospital, divided into 
those w
ith no or m
inor vs. m
ajor side effects 
Patient C
haracteristics 
 
Total 
(n=206) 
N
o or m
inor side 
 effects 
(n=136) 
M
ajor side  
effects 
(n=70) 
p-value 
A
ge  
years 
m
ean (SD
) 
77.6 (8.9) 
78.9 (8.9) 
76.9 (9.5) 
0.139 
Sex (fem
ale) 
no. fem
ale 
n (%
) 
147 (71.4) 
90 (66.2) 
57 (81.4) 
0.022 
Education 
years 
m
ean (SD
) 
12.5 (3.7) 
12.3 (3.8) 
12.7 (4.0) 
0.479 
M
M
SE 
score 
m
ean (SD
)  
25.3 (5.0) 
23.9 (6.3) 
25.2 (5.3) 
0.160 
Living in nursing hom
e 
no. 
n (%
) 
18 (8.7) 
9 (6.6) 
9 (12.9) 
0.133 
R
eceiving hom
e services 
no. 
n (%
) 
54 (26.2) 
36 (26.5) 
18 (25.7) 
0.907 
M
ore than 3 previous psychiatric 
adm
issions a 
no. 
n (%
) 
40 (19.4) 
26 (19.1) 
14 (20.0) 
0.879 
M
ain diagnosis dem
entia 
no. 
n (%
) 
76 (32.6) 
48 (35.3) 
16 (22.9) 
0.068 
M
ain diagnosis affective disorder 
no. 
n (%
) 
114 (48.9) 
52 (38.2) 
47 (67.1) 
<0.001 
M
ain diagnosis psychosis 
no. 
n (%
) 
19 (8.2) 
19 (14.0) 
0 
0.001 
N
um
ber of drugs for physical illness 
no. 
m
ean (SD
) 
4.5 (2.7) 
2.5 (2.0) 
3.7 (2.5) 
<0.001 
N
um
ber of psychotropic drugs c 
no. 
m
ean (SD
) 
1.6 (1.2) 
1.3 (1.2) 
2.2 (1.2) 
<0.001 
     U
sers of antidepressants 
no. 
n (%
) 
83 (40.3) 
40 (29.4) 
43 (61.4) 
<0.001 
     U
sers of benzodiazepines 
no. 
n (%
) 
113 (54.9) 
63 (46.3) 
50 (71.4) 
0.001 
     U
sers of antipsychotics 
no. 
n (%
) 
82 (39.8) 
52 (38.2) 
30 (42.9) 
0.521 
U
nreported use of psychotropic drugs c 
no. 
n (%
) 
89 (43.8) b 
52 (38.2) 
37 (52.9) 
0.044 
     O
ne or m
ore unreported antidepressant 
no. 
n (%
) 
14 
6 (4.4) 
8 (11.4) 
0.058 
     O
ne or m
ore unreported benzodiazepine 
no. 
n (%
) 
69 
41 (30.1) 
28 (40.0) 
0.156 
     O
ne or m
ore unreported antipsychotic 
no. 
n (%
) 
31 
20 (14.7) 
11 (15.7) 
0.848 
Serum
 concentration above reference 
range for psychotropic drugs  
no. 
n (%
) 
32  
18 (13.2) 
14 (20.0) 
0.204 
B
ody M
ass Index 
kg/m
2 
m
ean (SD
) 
24.5 (4.7) 
24.3 (4.5) 
24.8 (5.4) 
0.467 
C
harlson com
orbidity index 
no. 
m
ean (SD
) 
2.4 (2.3) 
2.1 (1.8) 
2.9 (2.6) 
0.015 
a Previous adm
issions to a psychiatric hospital b B
ased on num
ber of patients w
ith serum
 analysis, n=203. cIn total num
ber of 
psychotropic drugs and unreported use of drugs, lithium
 and antiepileptics are included. B
olded values: p<0.05, all characteristics 
w
ith a p-value <0.1 w
ere included in further analyses (except from
 sub-group variables. 
 
    T
able 2. Probable and possible side effects for the total group, m
easured by the U
K
U
 side effect rating scale divided into the five m
ain 
categories: Psychic, neurological, autonom
ic, other and cardiovascular side effects.  
 
 
Total G
roup 
N
o or m
inor side  effects (n=136) 
M
ajor side effects (n=70) 
Side effects 
 
 
N
um
ber of patients w
ith 
one or m
ore registered 
side effects N
 (%
) 
A
verage 
num
ber of side 
effects 
m
ean (SD
) 
N
um
ber of patients w
ith 
one or m
ore registered 
side effects N
 (%
) 
A
verage 
num
ber of side 
effects 
m
ean (SD
) 
N
um
ber of patients w
ith 
one or m
ore registered 
side effects N
 (%
)  
A
verage 
num
ber of 
side effects 
m
ean (SD
)  
Psychic 
107 (51.9) 
1.5 (1.9) 
48 (35.3) 
0.8 (1.4) 
59 (84.3) 
2.8 (2.2) 
N
eurological 
48 (23.3) 
0.4 (0.8) 
24 (17.6) 
0.3 (0.6) 
24 (34.3) 
0.7 (1.1) 
A
utonom
ic 
104 (50.5) 
1.0 (1.3) 
51 (37.5) 
0.6 (0.9) 
53 (75.7) 
1.8 (1.6) 
C
ardiovascular 
17 (8.3) 
0.1 (0.4) 
7 (5.1) 
0.1 (0.3) 
10 (14.3) 
0.2 (0.4) 
O
ther 
61 (29.6) 
0.5 (0.9) 
23 (16.9) 
0.2 (0.6) 
38 (54.2) 
1.0 (1.2) 
   
T
able 3. Logistic regression analysis of the predictive ability of patient characteristics for presence of side effects interfering m
oderately or m
arkedly w
ith 
the patient’s daily perform
ance (U
K
U
 G
lobal assessm
ent).  
 
 
O
dds ratio 
(unadjusted) 
95%
 C
onfidence 
interval for O
dds 
ratio 
(unadjusted) 
O
dds ratio 
(adjusted) 
95%
 C
onfidence interval 
for O
dds ratio  
(adjusted)  b 
p-value  
(adjusted) 
A
ge
a  
1.0 
1.0-1.0 
1.0 
0.9-1.0 
0.284 
Fem
ale G
ender 
2.2 
1.1-4.5 
2.4 
1.1-5.5 
0.035 
M
ain diagnosis of affective disorder 
3.3 
1.8-6.1 
4.3 
1.5-12.3 
0.006 
M
ain diagnosis of dem
entia 
0.5 
0.3-1.1 
0.3 
0.1-1.1 
0.068 
U
nreported use of psychotropic drugs 
1.8 
1.0-3.3 
2.0 
1.0-4.1 
0.047 
Total num
ber of som
atic drugs a 
1.3 
1.1-1.5 
1.2 
1.1-1.5 
0.009 
Total num
ber of psychotropic drugs a 
1.8 
1.4-2.3 
1.7 
1.2-2.3 
0.001 
C
harlson com
orbidity index
a 
1.2 
1.0-1.4 
1.2 
1.0-1.4 
0.031 
B
olded values: p<0.05, a continuous variables  badjusted for age, sex, diagnosis of affective disorder and dem
entia, unreported use of psychotropic drugs, 
total num
ber of som
atic and psychotropic drugs and C
harlson com
orbidity index. A
ll covariates had a p-value <0.1 in bivariate analyses, table 1. 
 
Table 4. Results from routine blood-screen on admission, with results divided in no or 
minor and major side effects and compared between the two groups, n=206. 
Bolded values: p<0.05 
 Unit No or minor 
side effects 
mean (SD) 
Major side 
effects 
mean (SD) 
p-value 
Erythrocyte sedimentation rate mm/hour 19.1 (18.8) 18.9 (18.2) 0.923 
White blood cells 109/l 6.9 (1.8) 7.4 (2.4) 0.113 
C-reactive protein mg/l 6.7 (14.0) 7.9 (17.4) 0.601 
Hemoglobin g/100ml 13.4 (1.6) 13.3 (1.7) 0.644 
Hematocrit % 0.64 (2.8) 0.40 (0.1) 0.471 
Red blood cells 1012/l 4.3 (0.6) 4.4 (0.6) 0.615 
Mean cell volume fl 93.5 (5.6) 92.3 (4.5) 0.108 
MCH pg 31.2 (2.1) 30.6 (1.9) 0.062 
MCHC g/100ml 33.4 0.8) 33.2 (1.0) 0.128 
Thrombocytes 109/l 296 (104.2) 294.0 (90.0) 0.879 
Vitamin B-12 pmol/l 405 (203.1) 438.6 (248.6) 0.301 
Folic acid nmol/l 18.6 (10.0) 21.4 (11.6) 0.082 
Natrium mmol/l 139.8 (3.3) 137.5 (16.5) 0.122 
Kalium mmol/l 4.1 (0.4) 4.1 (0.5) 0.980 
Calcium mmol/l 2.3 (0.1) 2.3 (0.1) 0.189 
Magnesium mmol/l 0.9 (0.1) 0.9 (0.1) 0.926 
Urea mmol/l 6.6 (2.8) 6.7 (3.6) 0.777 
Creatinin μmol/l 83.5 (30.4) 80.9 (32.3) 0.568 
Alanine aminotransferase U/l 24.3 (14.7) 33.1 (64.0) 0.129 
Gamma-glutamyl 
transpeptidase 
U/l 41.8 (46.8) 53.4 (87.9) 0.216 
Alkaline phosphatase U/l 81.8 (45.3) 82.1 (34.4) 0.969 
Albumin g/l 41.7 (3.9) 41.8 (4.0) 0.901 
Glucose mmol/l 5.9 (1.8) 5.5 (1.1) 0.137 
Thyroid stimulating hormone mIE/l 2.7 (5.6) 2.1 (2.3) 0.385 
T4 pmol/l 16.2 (3.0) 17.1 (3.0) 0.046 
Prolactin mIE/l 477 (469.1) 422.5 (359.6) 0.395 
INR - 2.2 (0.4) 2.6 (0.9) 0.249 
